Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME: Niraparib and Dostarlimab in HNSCC
NCT04681469Phase 2Recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Feb 2021
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, dostarlimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Gruppo Oncologico Nord Ovest. Started Feb 2021; status: recruiting.
02
Drugs
niraparibdostarlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04681469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04681469.